Shults C W, Haas R H, Beal M F
Department of Neurosciences, University of California, San Diego, La Jolla 92093, USA.
Biofactors. 1999;9(2-4):267-72. doi: 10.1002/biof.5520090223.
Parkinson's disease (PD) is a degenerative neurological disorder. Recent studies have demonstrated reduced activity of complex I of the electron transport chain in brain and platelets from patients with PD. Platelet mitochondria from parkinsonian patients were found to have lower levels of coenzyme Q10 (CoQ10) than mitochondria from age/sex-matched controls. There was a strong correlation between the levels of CoQ10 and the activities of complexes I and II/III. Oral CoQ10 was found to protect the nigrostriatal dopaminergic system in one-year-old mice treated with MPTP, a toxin injurious to the nigrostriatal dopaminergic system. We further found that oral CoQ10 was well absorbed in parkinsonian patients and caused a trend toward increased complex I activity. These data suggest that CoQ10 may play a role in cellular dysfunction found in PD and may be a potential protective agent for parkinsonian patients.
帕金森病（PD）是一种退行性神经疾病。最近的研究表明，帕金森病患者大脑和血小板中电子传递链复合体I的活性降低。帕金森病患者的血小板线粒体中辅酶Q10（CoQ10）水平低于年龄/性别匹配的对照组线粒体。CoQ10水平与复合体I和II/III的活性之间存在很强的相关性。在接受MPTP（一种对黑质纹状体多巴胺能系统有害的毒素）治疗的一岁小鼠中，发现口服CoQ10可保护黑质纹状体多巴胺能系统。我们进一步发现，口服CoQ10在帕金森病患者中吸收良好，并导致复合体I活性有增加的趋势。这些数据表明，CoQ10可能在帕金森病中发现的细胞功能障碍中起作用，并且可能是帕金森病患者的潜在保护剂。
